首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1419133

特發性肺纖維化治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類型、配銷通路和地理位置

Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Type, Distribution Channel, and Geography

出版日期: 2023年12月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

全球特發性肺纖維化治療市場規模預計將從2022年的43.6億美元激增至2030年的107.84億美元；預計 2022 年至 2030 年該市場將以 12.0% 的CAGR成長。

吸菸人數的增加推動了特發性肺纖維化治療市場的成長

吸菸是發生特發性肺纖維化的眾所周知的危險因子之一。最近的研究表明，吸菸可能對特發性肺纖維化治療患者的生存產生不利影響。幾項研究提供的證據表明，氧化壓力增加可能會促進目前和先前吸菸者的特發性肺纖維化患者的疾病進展。

香菸煙霧中含有粒狀物、劇毒活性氧和活性氮（RONS）以及其他化學物質。這些成分會引發體內腫脹，導致各種疾病，包括肺纖維化和癌症。根據美國疾病管制與預防中心(CDC) 2023 年5 月發布的最新數據，美國18 歲及以上成年人中，每100 名成年人中約有12 名（約佔人口的11.5%）吸煙，美國成年吸菸者總數為2,830 萬人。因此，吸菸人數的激增預計將推動特發性肺纖維化治療市場的成長。

特發性肺纖維化負擔的增加推動了特發性肺纖維化治療市場的成長

根據美國肺臟協會 2022 年 11 月更新的資料，美國每年診斷出約 5 萬例新發特發性肺纖維化病例。這種情況的症狀在 50-70 歲的患者身上更為明顯。根據 2022 年 9 月發表在《英國醫學雜誌》上的一篇文章，預計 2021 年專科護理病房中特發性肺纖維化的盛行率為每 10 萬人中 36.0 人。由於老化、肥胖、高血壓或家族史等常見危險因素，全世界患有特發性肺纖維化的患者數量不斷增加，且該疾病正在成為經濟體的重大社會經濟負擔。因此，特發性肺纖維化患者數量的增加推動了纖維化疾病治療市場的成長。

基於藥物類型的見解

依藥物類型，特發性肺纖維化治療市場分為尼達尼布、吡非尼酮等。尼達尼布細分市場在 2022 年佔據更大的市場佔有率。預計其他細分市場在 2022 年至 2030 年期間的CAGR將達到 46.3%。吡非尼酮和尼達尼布是治療纖維化疾病的常用藥物。

基於配銷通路的見解

依配銷通路，全球特發性肺纖維化治療市場分為醫院藥房、零售藥房和網路藥房。醫院藥局細分市場在 2022 年佔據最大市場佔有率。線上藥局細分市場預計 2022 年至 2030 年CAGR最高，達到 17.4%。

領先企業正在實施策略，例如擴大市場佔有率和多元化、推出新產品以及獲取新客戶群，以挖掘現有商機。

2023 年5 月，Cumberland Pharmaceuticals Inc. 宣布其II 期臨床試驗的研究性新藥申請(IND) 獲得FDA 批准，該試驗重點關注患有特發性肺纖維化的患者，特發性肺纖維化是進行性纖維化肺部疾病的主要形式。這項批准代表了特發性肺纖維化潛在治療方法向前邁出的關鍵一步，並給受這種挑戰性疾病影響的人們帶來了希望。

2022 年10 月，勃林格殷格翰在評估BI 1015550 的FIBRONEER-IPF III 期研究中招募了第一位美國患者。BI 1015550 是一種實驗性磷酸二酯酶4B (PDE4B) 抑制劑，被發現用於治療患有特發性肺纖維化的個體。該研究是全球FIBRONEER 計劃的一部分，該計劃包括兩項III 期研究：針對特發性肺纖維化患者的FIBRONEER-IPF 和針對患有其他進行性纖維化間質性肺疾病(ILD) 的成人患者的FIBRONEER-ILD。

2022 年 6 月，Accord Healthcare, Inc. 宣布將吡非尼酮加入其固體口服產品組合。這種新藥被批准用於治療特發性肺纖維化，因為它的治療效果與基因泰克公司的 Esbriet 相當。

2022年5月，山德士推出了學名藥吡非尼酮，這是第一個AB級（完全可替代）的學名藥，相當於基因泰克的Esbriet，用於治療特發性肺纖維化患者。這種口服藥物透過專科藥房以 0 美元共付額計劃向符合條件的患者提供。

2022年3月，領先的製藥公司百時美施貴寶宣布透過最終合併協議以每股76.00美元收購Turning Point Therapeutics, Inc.。此次收購顯著增強了百時美施貴寶在製藥市場的全球影響力，使其能夠更加積極主動地為產業帶來創新，同時擴大其挽救生命的療法和治療組合。

2021年6月，羅氏集團成員基因泰克向美國食品藥物管理局（FDA）提交補充新藥申請（sNDA）後，Esbriet（吡非尼酮）獲得優先審查

美國食品藥物管理局、疾病管制與預防中心 (CDC) 和全球疾病負擔研究是準備特發性肺纖維化治療市場報告時參考的主要和次要來源。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 10 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 11 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 12 章：特發性肺纖維化治療市場 - 主要公司概況

F. Hoffmann-La Roche Ltd

注意 - 將為以下公司列表提供類似資訊

勃林格殷格翰
阿斯利康
百時美施貴寶
鹽野義株式會社
西普拉有限公司
其他

第 13 章：附錄

詞彙表
關於 Insight Partners
市場情報雲

簡介目錄

Product Code: TIPRE00005557

The global idiopathic pulmonary fibrosis treatment market size is projected to surge from US$ 4.360 billion in 2022 to US$ 10.784 billion by 2030; the market is estimated to grow at a CAGR of 12.0% during 2022-2030.

Increasing Number of People Smoking Cigarettes Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth

Cigarette smoking is one of the well-known risk factors for the development of idiopathic pulmonary fibrosis. Recent studies suggest that smoking may have a detrimental effect on the survival of patients with idiopathic pulmonary fibrosis treatment. Several studies have produced evidence suggesting that increased oxidative stress may promote disease progression in idiopathic pulmonary fibrosis patients who are current and former smokers.

Cigarette smoke contains particulate matter, highly toxic reactive oxygen and nitrogen species (RONS), and other chemicals. These constituents trigger swelling in the body and thus lead to various diseases, including pulmonary fibrosis and cancer. According to the Centers for Disease Control and Prevention (CDC) updates released in May 2023, approximately 12 out of 100 adults (~11.5% of the population) aged 18 and older in the US smoke cigarettes, totaling 28.3 million adult smokers in the US. Therefore, an upsurge in the number of people smoking cigarettes is expected to drive the growth of the idiopathic pulmonary fibrosis treatment market.

Growing Burden of Idiopathic Pulmonary Fibrosis Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth

According to data from the American Lung Association, updated in November 2022, approximately 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed in the US each year. Symptoms of this condition are more noticeable in patients of age 50-70. According to an article published in the British Medical Journal in September 2022, the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is increasing worldwide due to common risk factors such as aging, obesity, high blood pressure (hypertension), or family history, and the condition is becoming a significant socioeconomic burden for economies. Therefore, the increasing number of patients with idiopathic pulmonary fibrosis propels bolsters the fibrotic disease treatment market growth.

Drug Type -Based Insights

Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022-2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.

Distribution Channel -Based Insights

By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022-2030.

Leading players are implementing strategies such as expansion and diversification of their market presence, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.

In May 2023, Cumberland Pharmaceuticals Inc. announced receiving FDA approval for its Investigational New Drug Application (IND) for a Phase II clinical trial focused on patients suffering from idiopathic pulmonary fibrosis, the predominant form of progressive fibrosing lung disease. This approval represents a critical step forward in the advancement of potential treatments for idiopathic pulmonary fibrosis and gives hope to those affected by this challenging disease.

In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550. BI 1015550 is an experimental phosphodiesterase 4B (PDE4B) inhibitor discovered for treating individuals suffering from idiopathic pulmonary fibrosis. The study is a part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF in patients with idiopathic pulmonary fibrosis and FIBRONEER-ILD in adults with other progressive fibrosing interstitial lung diseases (ILDs).

In June 2022, Accord Healthcare, Inc. announced the addition of pirfenidone to its solid oral product portfolio. This new drug is approved for the treatment of idiopathic pulmonary fibrosis, as it is therapeutically equivalent to Genentech's Esbriet.

In May 2022, Sandoz launched its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech's Esbriet, for the treatment of patients with idiopathic pulmonary fibrosis. This oral medication was made available for eligible patients through specialty pharmacies with a $0 copay program.

In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition has significantly strengthened Bristol Myers Squibb's global presence in the pharmaceutical market, allowing it to be more proactive in bringing innovations to the industry while expanding its portfolio of life-saving therapies and treatments.

In June 2021, Genentech, a member of the Roche Group, was granted a priority review FOR Esbriet (pirfenidone) after it submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA)

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the idiopathic pulmonary fibrosis treatment market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Idiopathic Pulmonary Fibrosis Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Idiopathic Pulmonary Fibrosis Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Idiopathic Pulmonary Fibrosis Treatment Market - Global Market Analysis

6.1 Idiopathic Pulmonary Fibrosis Treatment - Global Market Overview
6.2 Idiopathic Pulmonary Fibrosis Treatment - Global Market and Forecast to 2030

7. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

7.1 Overview
7.2 Nintedanib
7.3 Pirfenidone
7.4 Others

8. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

8.1 Overview
8.2 Hospitals Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies

9. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

9.1 North America
- 9.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
- 9.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts to 2030
- 9.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
- 9.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By End User
- 9.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  - 9.1.5.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  - 9.1.5.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Idiopathic Pulmonary Fibrosis Treatment Market - Key Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies